Engineered immune cells take on tough lupus cases

NCT ID NCT07444307

First seen Mar 13, 2026 · Last updated May 12, 2026 · Updated 3 times

Summary

This early-phase study tests an experimental treatment called QT-019B for people with refractory systemic lupus erythematosus (SLE) that hasn't responded to standard therapies. The treatment uses specially engineered immune cells (CAR-T cells) from a healthy donor to target and potentially reset the immune system. The main goals are to check safety and find the right dose, while also monitoring how well it controls lupus disease activity.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking Union Medical College Hospital

    RECRUITING

    Beijing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Ustc Anhui Provincial Hospital

    RECRUITING

    Hefei, Anhui, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.